<div id="readability-page-1"><div><p><span>Suzhou Zelgen Biopharmaceuticals Co Ltd </span><span>:</span></p><ul><li>SAYS ITS ZG006 FOR INJECTION HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF NEUROENDOCRINE CARCINOMA</li></ul></div></div>

688266

<p>Suzhou Zelgen Biopharmaceuticals Co Ltd :SAYS ITS ZG006 FOR INJECTION HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF NEUROENDOCRINE CARCINOMA</p>

Suzhou Zelgen Says ZG006 Has Received Orphan Drug Designation From U.S. FDA